Released May 13, 2025, after the close
10-Q filed May 13, 2025, 43 days after period end · 0000950170-25-070285
Q1 2025 · 10-Q
Revenue$1.63M$1.63M −15.4% vs Q1 2024−12.4% vs Q4 2024
Net Income-$37.62M-$37.62M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.32-$0.32 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$41,280,000N/M
Operating Cash Flow-$33,809,000N/M
Free Cash Flowderived-$35,005,000N/M
Margins · derived
Operating margin-2534.1%+118.8 pt vs Q1 2024
Net margin-2309.5%+184.3 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $1.63M | $1.93M | $58.98M | $18.41M |
| Net Income | -$37.62M | -$48.00M | -$18.88M | -$65.69M |
| EPS Diluted | -$0.32 | -$0.47 | -$0.19 | -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR